Overview

Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy. The study will use a central randomization with a dynamic allocation using biased coin minimization.
Phase:
Phase 3
Details
Lead Sponsor:
Zeria Pharmaceutical
Treatments:
Specific substance maruyama